GSK says its PD-1 inhibitor Jemperli compared favourably with Merck & Co’s Keytruda in a head-to-head trial in previously-untreated non-small cell lung cancer (NSCLC), with numerically
$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but, in fact, it comes from diminutive biotech Summit Therapeutics.
The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea's Hanmi Pharma, which origi
